Eisai R&d Management Co., Ltd.

Genentech, Inc.

Forma Tm, LLC

Millennium Pharmaceuticals Limited

Valo Health, Inc.

Other

Dominic J Reynolds

Xiaozhang Zheng

Kenneth W Bair

Bingsong Han

Zhongguo Wang

Alexandre Joseph Buckmelter

Jian Lin

Chase C Smith

Timm R Baumeister

Karl H Clodfelter

Sudeep Prajapati

Po-Wai Yuen

John JianShi Wang

Peter Scott Dragovich

Francis Gosselin

Ming-Hong Hao

Bruce D Roth

Francois Soucy

Andrew Cook

Takashi Satoh

Xiang Liu

Anand Selvaraj

James Palacino

Shelby Ellery

Amy M Elder

Thiwanka Samarakoon

Megan Sheehan

Nathan Elliott Fishkin

Tricia J Vos

Ping Zhu

Gang Li

Peter G Smith

Indu T Bharathan

Matthew O Duffey

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Michael W Seiler

Jianping Guo

Zhenhua Wu

Nicholas Calandra

Yonghong Xiao

Julie Fields Liu

Paul E Fleming

Jason T Lowe

Michael E Hepperle

Jeremy D Little

Judith D Kuntz

Shouyong Peng

Alfredo C Castro

Shomir Ghosh

Kenneth Gordon Carson

Guo Zhu Zheng

Atsushi Endo

Yoshihiko Kotake

Guiling Zhao

Mark Edward Zak

Geraldine C B Harriman

Kevin Sprott

Gregg F Keaney

Prakash Raman

Kazunobu Kira

Marta Nevalainen

Parcharee Tivitmahaisoon

Cheng Zhong

Arani Chanda

Norio Murai

Yingchun Ye

Janet L Gunzner-Toste

Kristen Sanders

Yamin Zhang

George Moniz

Baudouin Gerard

Hormoz Mazdiyasni

Sean J Harrison

Kenshi Yoshida

Christelle C Renou

Satoshi Nagao

Frederick A Hicks

Masayuki Miyano

Xiongcai Liu

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Lisa A Marcaurelle

Robert S Murray

Raman Prakash

Ryan Brawn

Morgan Welzel O'shea

Tuoping Luo

Sundeep Prajapati

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

Compounds and compositions for the inhibition of NAMPT

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Certain aryl pladienolide compounds and methods of use

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: 

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

Crystalline FGFR4 inhibitor compound and uses thereof

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I) 

Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA. 

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Pyrimidine FGFR4 inhibitors

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Amido-benzyl sulfone and sulfoxide derivates

Growing community of inventors

Watertown, MA, United States of America

Dominic J Reynolds